Morning Movers: BIDU, WGP, NERV, INFI

 | Jun 14, 2016 | 8:23 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:








As oil prices continued their six-day slide Tuesday, now well below their $50 peak last week, U.S. futures fell slightly in premarket trading. The S&P 500, Dow Jones industrials and Nasdaq were each down about 0.2%. Meanwhile, crude oil slid 1.4% to $48.19 a barrel, based on U.S. benchmark West Texas Intermediate.

Baidu (BIDU) shares fell about 4% in premarket trading Tuesday after the Chinese e-commerce giant cut its second-quarter sales forecast by more than 10% to a range of 18.1 billiion yuan to 18.2 billion yuan, or roughly $2.75 billion, amid a decline in advertising sales. The company's CEO, Robin Li Yanhong, said on a morning call with analysts that the projections are primarily the result of uncertainty surrounding regulation in the medical industry causing several medical advertisers to cut spending.

Shares of Western Gas Equity Partners (WGP) were down about 10% on news that the Houston-based subsidiary of Andarko Petroleum (APC) unveiled pricing on a limited-partner offering of 12.5 million common units of $481 million. Goldman Sachs and Morgan Stanley were joint underwriters on the deal and were given a 30-day option to purchase an additional 1.88 million common units as part of the settlement, which is set to close Friday.

Meanwhile, Infinity Pharmaceuticals (INFI) shares dropped about 63% in premarket trading on news it expects to incur about $6 million to $8 million in costs tied to restructuring plans, noting the Cambridge, Mass.-based drugmaker also expects to make about $5 million in additional cash payments for various costs including severance and benefits.

Shares of Minerva Neurosciences (NERV) also dipped about 4% on news the Waltham, Mass.-based drugmaker has tapped Jefferies investment bankers to prepare to issue an unspecified amount of common stock in order to fund the continued development of its products. Minerva stock most recently jumped more than 50% in May on news that a drug aimed to treat schizophrenia successfully completed mid-stage trials.

Columnist Conversations

I recently highlighted WBA as one of the best values available in today's market. Walgreens ...
This trade is NOT for everyone (GE) came very close the 3/26 low @ 12.73 Gaps lower has been a recent daily e...
The support I needed to hold in XLB did not, so the trade is a bust......There may be some lower support at th...
British American Tobacco (BTI) is trading near multi-year lows, yielding 5.6% and about to ex-dividend on June...



News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.